Theophylline Tablets or Capsules |
Accurbron; Aquaphyllin; Asmalix; Bronkodyl; Elixomin; Elixophyllin; Lanophyllin; Quibron-T Dividose; Slo-Phyllin; Theoclear-80; Theolair; Theostat 80 |
Clinical Trial: Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secrectory Conversion
This study is currently recruiting patients.
Verified by Solvay Pharmaceuticals September 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Secondary Amenorrhea | Drug: progesterone | Phase IV |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Evaluation of Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding in Subjects with Secondary Amenorrhea
Eligibility
Inclusion Criteria:
Women 18-45 with secondary amenorrhea, Serum FSH ≤ 5 IU/L or ≥20 IU/L, serum estradiol ≤100 pg/ml. serum prgesterone ≤1 ng/ml. Normal serum DHEA, prolactin, testosterone, TSH and thyroxine
Exclusion Criteria:
Primary Amenorrhea, Asherman''''s syndrome,peanut allergy, allergy to progestational steroids,
Location and Contact Information
Alabama
Site 41, Montgomery, Alabama, United States; Recruiting
Site 29, Mobile, Alabama, United States; Recruiting
Arizona
Site 26, Tucson, Arizona, United States; Recruiting
Arkansas
Site 5, Jonesboro, Arkansas, United States; Recruiting
California
Site 10, San Diego, California, United States; Recruiting
Site 17, Encinitas, California, United States; Recruiting
Site 39, Carmichael, California, United States; Recruiting
Connecticut
Site 3, Groton, Connecticut, United States; Recruiting
Site 9, Waterbury, Connecticut, United States; Recruiting
Site 22, New Britain, Connecticut, United States; Recruiting
Site 42, Avon, Connecticut, United States; Recruiting
Site 37, West Hartford, Connecticut, United States; Recruiting
Florida
Site 1, West Palm Beach, Florida, United States; Recruiting
Site 14, Aventura, Florida, United States; Recruiting
Site 30, West Palm Beach, Florida, United States; Recruiting
Site 40, Clearwater, Florida, United States; Recruiting
Georgia
Site 43, Powder Springs, Georgia, United States; Recruiting
Illinois
Site 12, Chicago, Illinois, United States; Recruiting
Site 36, Champaign, Illinois, United States; Recruiting
Louisiana
Site 6, Baton Rouge, Louisiana, United States; Recruiting
Maryland
Site 7, Baltimore, Maryland, United States; Recruiting
Missouri
Site 2, St. Louis, Missouri, United States; Recruiting
Nevada
Site 16, Reno, Nevada, United States; Recruiting
North Carolina
Site 15, Winston Salem, North Carolina, United States; Recruiting
Site 23, New Bern, North Carolina, United States; Recruiting
Site 28, Winston Salem, North Carolina, United States; Recruiting
Ohio
Site 33, Cincinnati, Ohio, United States; Recruiting
Pennsylvania
Site 32, Erie, Pennsylvania, United States; Recruiting
Site 38, Pottstown, Pennsylvania, United States; Recruiting
South Carolina
Site 13, Greenville, South Carolina, United States; Recruiting
Texas
Site 8, Conroe, Texas, United States; Recruiting
Site 11, Corpus Christi, Texas, United States; Recruiting
Site 34, Houston, Texas, United States; Recruiting
Site 24, San Antonio, Texas, United States; Recruiting
Site 27, Houston, Texas, United States; Recruiting
Utah
Site 35, Salt Lake City, Utah, United States; Recruiting
Virginia
Site 19, Norfolk, Virginia, United States; Recruiting
Washington
Site 4, Seattle, Washington, United States; Recruiting
Global Clinical Director Solvay, Study Director, Solvay Pharmaceuticals
More Information
Last Updated: September 11, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00160199
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13

Not Signed In -


